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A B S T R A C TObjectives: To develop a mapping model for estimating six-
dimensional health state short form (SF-6D) utility scores
from the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaires (QLQ-C30 and QLQ-CR29) scores
in patients with colorectal cancer (CRC), with and without adjustment
for clinical and demographic characteristics. Methods: Ordinary
least squares regression models were applied to a cross-sectional
data set of 216 patients with CRC collected from a regional hospital in
Hong Kong. Item responses or scale scores of cancer-specific (QLQ-
C30) and colorectal-specific health-related quality-of-life (QLQ-CR38/
CR29) data and selected demographic and clinical characteristics
of patients were used to predict the SF-6D scores. Model goodness
of fit was examined by using exploratory power (R2 and adjusted R2),
Akaike information criterion, and Bayesian information criterion,
and predictive performance was evaluated by using root mean
square error, mean absolute error, and Spearman’s correlation
coefficients between predicted and observed SF-6D scores. Models
were validated by using an independent data set of 56 patients
with CRC. Results: Both scale and item response models explainedsee front matter Copyright & 2013, International
r Inc.
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nic, 161 Ap Lei Chau Main Street, Ap Lei Chau, Hmore than 67% of the variation in SF-6D scores. The best-performing
model based on goodness of fit (R2 ¼ 75.02%), predictive ability
in the estimation (root mean square error ¼ 0.080, mean absolute
error ¼ 0.065), and validation data set prediction (root mean
square error ¼ 0.103, mean absolute error ¼ 0.081) included variables
of main and interaction effects of the QLQ-C30 supplemented by QLQ-
CR29 subset scale responses and a demographic (sex) variable.
Conclusions: SF-6D scores can be predicted from QLQ-C30 and
QLQ-CR38/CR29 scores with satisfactory precision in patients with
CRC. The mapping model can be applied to QLQ-C30 and QLQ-CR38/
CR29 data sets to produce utility scores for the appraisal of clinical
interventions targeting patients with CRC using economic
evaluation.
Keywords: colorectal cancer, EORTC QLQ-C30, mapping, preference-
based scores, quality of life, SF-6D.
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Under the constraints of resource limitations, health policy
makers usually allocate available resources among health inter-
ventions on the basis of their clinical performances. This does
not, however, take cost and comparable benefit into account,
meaning that the allocation of resources may be suboptimal.
Colorectal cancer (CRC) impacts a heavy economic burden of
disease in the world because of its relatively high incidence rates
and treatment costs [1]. Cost-utility analysis is conducted by
using the cost per quality-adjusted life-year (QALY) gained to
critically appraise the emerging alternatives of costly therapies
and interventions for CRC. The QALYs for each CRC health state
can be calculated by using direct elicitation methods involving
the use of standard gamble or time trade-off techniques [2–5] orpreference-based measures such as the EuroQol five-dimensional
(EQ-5D) questionnaire [6], six-dimensional health state short
form (derived from short-form 36 health survey) (SF-6D) [7],
health utilities index [8], and European Organization for Research
and Treatment of Cancer (EORTC)-8D [9]. UK national guidelines
regarding health technology appraisal [10] recommend the use of
generic preference-based measures, and further states a prefer-
ence for the EQ-5D questionnaire. When the EQ-5D questionnaire
is unavailable, it is recommended that the EQ-5D questionnaire
data be estimated by using ‘‘mapping.’’
According to a recent literature review [11], there is a growing
body of literature on mapping functions of ‘‘source’’ health-related
quality-of-life (HRQOL) measures onto ‘‘target’’ preference-based
measures based on regression models. Two core modules of
cancer-specific HRQOLmeasures are often used to measure overallSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
amily Medicine and Primary Care, The University of Hong Kong,
ong Kong.
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tional Assessment of Cancer Therapy-General (27 items) [12] and
the EORTC Core Quality of Life Questionnaire (QLQ-C30, 30 items)
[13]. In addition to cancer-specific HRQOLmeasures, the Functional
Assessment of Cancer Therapy-Colorectal [14] and EORTC Color-
ectal Cancer-specific Quality of Life Questionnaire (QLQ-CR38, 38
items) [15] are widely used colorectal-specific HRQOL measures.
The Chinese versions of all aforementioned questionnaires have
been validated in Hong Kong Chinese patients [16,17]. The QLQ-
CR38 was superseded by the QLQ-CR29, which was an updated and
improved version of the colorectal-specific measure [18].
The majority of mapping functions available used the EQ-5D
questionnaire as their target measure [11], probably due to the
preference for the use of the EQ-5D questionnaire in technology
appraisals submitted to the National Institute for Health and
Clinical Excellence [10]. Eight studies [19–26] used QLQ-C30 data
to predict EQ-5D questionnaire utility scores but only one study
mapped the EORTC QLQ-C30 to SF-6D utility score derived by
using the UK value set [25]. No mapping function for the EORTC
QLQ-C30 has ever been done in Chinese populations. Health
preference varies systematically across countries because of
cultural differences, and therefore preference weighting of
preference-based measures is preferably based on local popula-
tion valuations. The SF-6D is the only multiattribute classification
system that has a preference weighting algorithm specific to the
Chinese population [27], which makes mapping functions target-
ing to SF-6D more applicable and valid in our setting.
Despite the evidence that the development of mapping func-
tions was frequently built on patients with cancer condition [28],
none of them was specific to patients with CRC. Although numer-
ous studies have developedmapping functions that predicted utility
scores by using QLQ-C30 data across a range of different cancer
patients groups [19–26,29], no study has mapped from the EORTC
CRC-specific module (QLQ-CR38 and QLQ-CR29) to any preference-
based measure. Since then, the primary aim of this study was to
map from the EORTC cancer-specific and CRC-specific scale scores
or item responses to SF-6D preference-based utility scores in
patients with different stages of CRC, adjusting for demographic
factors. This mapping function enabled researchers to conduct
health economic appraisals of population-based screening and
treatment modalities for CRC where data have been collected only
by using non–preference-based cancer-specific measures.Methods
Subjects
This study was a secondary analysis of data obtained from a
health survey to examine the HRQOL profile and preference-based
scores of patients with colorectal neoplasms in a Chinese popula-
tion [16,30–32]. Study data were obtained from a cross-sectional
survey of 587 adult patients attending the colorectal specialist
outpatient clinic of an academic teaching hospital in Hong Kong
between October 2009 and July 2010. Data of 272 patients with
known staged CRC (using the American Joint Committee on
Cancer classification) who had completed the cancer-specific
QLQ-C30, CRC-specific QLQ-CR38, and generic SF-6D instruments
were separated into two samples, one (self-administration ¼ 216,
79.4%) for model development and the other (interviewer-admin-
istration ¼ 56, 20.6%) for model validation.
HRQOL Measures
EORTC Measure
The Traditional Chinese version 3 of the QLQ-C30 is a cancer-
specific HRQOL instrument [13,17] that has a global health statusand quality-of-life scale (QL), five functional scales (physical
functioning, PF; role functioning, RF; emotional functioning, EF;
cognitive functioning, CF; and social functioning, SF), and nine
symptom scales/items (fatigue, FA; nausea and vomiting, NV; pain,
PA; dyspnea, DY; insomnia, SL; appetite loss, AP; constipation, CO;
diarrhea, DI; and financial difficulties, FI) specific to cancer. The QL
scale of the QLQ-C30 consists of two items measuring the degree
to which the overall quality of life was subjectively perceived by
patients, using a seven-point Likert scale ranging from 1 ¼ ‘‘Very
poor’’ to 7 ¼ ‘‘Excellent.’’ All items in other scales are scored by
using a four-point Likert scale (1 ¼ ‘‘Not at all,’’ 2 ¼ ‘‘A little,’’ 3 ¼
‘‘Quite a bit,’’ and 4 ¼ ‘‘Very much’’). To facilitate mapping from the
existing data set containing QLQ-C30 only, mapping functions
were estimated by using 30 items of the QLQ-C30 as explanatory
variables. Moreover, the CRC-specific QLQ-CR38 encompasses four
functional scales and seven symptom scales or items [15]. Both
colorectal-specific QLQ-CR38 and QLQ-CR29 are additional ques-
tionnaire modules that require supplemental use in conjunction
with the QLQ-C30. In an attempt to make the mapping functions
applicable to utilization in data sets containing either QLQ-CR38 or
QLQ-CR29, mapping functions were estimated by using 30 items of
the QLQ-C30 plus only the 10 items of the QLQ-CR38 as explana-
tory variables. Those items have the same wording or phrase as
the corresponding QLQ-CR29 items [18] labeled as QLQ-CR29subset,
representing two functional scales (body image, BI; anxiety, ANX)
and five symptom scales/items (urinary frequency, UF; dysuria,
DYSU; abdominal pain, APAIN; bloating, BF; and dry mouth, DM).
Their content validity was supported by a study on patients with
CRC who rated these items relevant and acceptable [33].
The raw score of each scale is summed and rescaled to range
from 0 to 100, according to the standardized EORTC scoring
guidelines [34]. Higher scores in global and functional scales
but lower scores in symptom scales indicate better HRQOL.
SF-6D
The SF-6D is a widely used preference-based generic HRQOL
measure with a multiattribute classification system consisting of
six dimensions: physical functioning, role functioning, social
functioning, pain, mental health, and vitality. Each dimension
is composed of three to five levels. The health status described by
the combination of six dimensional attributes was converted into
an SF-6D value by applying preference weights derived from the
general population. Population-specific SF-6D preference weights
had been elicited in the United Kingdom [7], our local Hong Kong
Chinese population [27,35], and other populations [36,37]. The
Hong Kong weights were used in the current study. The Hong
Kong population SF-6D values range from 0.315 to 1, with higher
scores indicating better HRQOL anchoring on the 0 (dead) to 1
(full health) scale.
Statistical Analysis
Model Development and Specifications
Therefore, 12 model specifications were estimated, where SF-6D
was regressed on S1) QLQ-C30 scale scores, S2) as per S1 plus
squared and pair-wise interaction terms, S3) as per S2 plus
demographic and clinical variables, S4) QLQ-C30 and QLQ-
CR29subset scale scores, S5) as per S4 plus squared and pair-wise
interaction terms, S6) as per S5 plus demographic and clinical
variables, R1) QLQ-C30 raw responses, R2) as per R1 plus squared
and pair-wise interaction terms, R3) as per R2 plus demographic
and clinical variables, R4) QLQ-C30 and QLQ-CR29subset raw
responses, R5) as per R4 plus squared and pair-wise interaction
terms, and R6) as per R5 plus demographic and clinical variables.
To ensure direct comparability of different models, only cases
(n ¼ 216) with complete data of all variables involved in the
modeling process were used throughout the analysis.
Fig. 1 – Distributions of the SF-6D scores based on model
development (upper) and validation (lower) samples. SF-6D,
six-dimensional health state short form.
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diction models of SF-6D in forward stepwise selection approach.
Initially, the SF-6D score was regressed on the main effects of the
scale scores. Only those significant variables were retained in the
next model. Significant squared and pair-wise interaction terms
of the selected scale scores were added to the model to account
for possible nonlinearity. Because of the principle of hierarchy,
the corresponding lower-order main effect terms must be
retained in the model even if their coefficients became insignif-
icant. In the final model, three clinical variables of American Joint
Committee on Cancer (AJCC) cancer staging, treatment active,
and stoma and two demographic variables of sex and age were
added as explanatory variables. The F test was used to determine
which variables to retain with an inclusion criterion of P value
lower than 0.05 and exclusion criterion of P value greater than
0.10. If the P value of any second-order term added in the former
phases exceeded 0.10 in a later model, the term would be
removed from the model process but would be considered for
reentry in the final model. The analysis was repeated by using the
QLQ-C30 and QLQ-CR29subset items as explanatory variables. The
data set had good coverage of possible responses to SF-6D, QLQ-
C30, and QLQ-CR29subset, where only four items did not have
responses across every severity level (level 1 of Q29 and Q30, level
4 of Q14 and Q15 [see Table in Appendix 1 of Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2012.12.004 for
the responses of each item]). For items with a low number (o5%)
of responses at the most extreme level, responses were merged
with the adjacent level unless the item had two levels.
Ordinary least squares estimation is most widely used for the
development of mapping models [11]. In recent years, there has
been an increasing interest in the use of different model types
that are more appropriate for the distribution of EQ-5D ques-
tionnaire data, which is bi- or trimodal, with typically a large
percentage of responses at 1. Although the Kolmogorov-Smirnov
test failed to show the normal distribution of SF-6D based on
samples of model development (P o 0.001) and validation
(P o 0.001), the test was typically sensitive to reject the null
hypothesis. Figure 1 illustrates SF-6D distribution on the basis of
data of model development and validation, meaning that ordin-
ary least squares is appropriate, and it was therefore used in this
article. The ordinary least squares model is basically character-
ized as the unbiased estimation of parameters if the assumption
on homogeneity of residual variance holds. The residual plots for
the final models were used as the primary tool to examine the
model adequacy such as the nonnormality and heteroscedasti-
city within the data.Model Validation and Comparison
Model goodness of fit was assessed by R2 and adjusted R2
statistics, Akaike information criteria (AIC), and Bayesian infor-
mation criteria (BIC) statistics. R2 and adjusted R2 statistics
measured the explanatory power of a model, that is, how much
of the variability in the dependent variable can be explained by
the predictors. The goodness of fit was also described by using
AIC and BIC statistics, with the lower values indicating better fit.
Spearman’s correlation coefficients (r) and intraclass correlation
coefficients were calculated to assess the relationship between
predicted and observed SF-6D scores. To further assess the
predictive ability of a model, the differences between the pre-
dicted and observed SF-6D scores at the individual level were
examined by computing root mean square error (RMSE) and
mean absolute error (MAE). In addition, the number of observa-
tions and the corresponding proportions in the sample where the
absolute error was greater than 0.05 and 0.10, respectively, were
calculated. The ranges of the achievable SF-6D scores from theresulting mapping functions were compared with the range of
the SF-6D scores computed by the standard algorithm.
To assess the predictive performance of the mapping func-
tions, an out-of-sample validation was performed by using QLQ-
C30, QLQ-CR29subset, and SF-6D data from the validation data set,
which was not used for model development. The mapping
functions developed in this article were used to produce pre-
dicted SF-6D scores, and the predictive ability of the models was
explored by comparing predicted and observed SF-6D scores by
using both the model development sample and an out-of-sample
validation data set. These results were compared with predic-
tions obtained by applying an existing SF-6D mapping function
created by Kontodimopoulos et al. [25].
All regressions and other analyses were conducted by using
SPSS version 20.0 (SPSS, IBM, Inc., Chicago, IL, USA).Results
Descriptive Statistics for SF-6D and EORTC
Demographic and clinical characteristics of patients are shown in
Table 1. The model development and validation groups were
statistically different for age, sex, education level, marital status,
and working status but not in clinical characteristics.
Table 2 shows the observed SF-6D, QLQ-C30, and QLQ-CR29subset
scale of the model development and validation groups. Mean
SF-6D score was statistically different, but most QLQ-C30 and
Table 1 – Demographic and clinical characteristics of study subjects.
Model development (n ¼ 216) Model validation (n ¼ 56) Total (n ¼ 272) P
Age (y), mean  SD 61.6  11 65  11.1 62.3  11.1 0.041
Sex (%) 0.025
Male 56.0 39.3 52.6
Female 44.0 60.7 47.4
Education level (%) o0.001
No formal school 8.3 28.6 12.5
Primary 31.0 30.4 30.9
Secondary 44.0 35.7 42.3
Tertiary 16.7 5.4 14.3
Marital status (%) 0.029
Married 76.9 62.5 73.9
Not married 23.1 37.5 26.1
Currently working (%) 0.009
Yes 27.3 21.4 26.1
No 72.7 78.6 73.9
Income (%) 0.109
rHKD$20,000 81.7 90.7 83.5
4HKD$20,000 18.3 9.3 16.5
Smoking (%) 0.893
Ever had 24.1 23.2 23.9
Never had 75.9 76.8 76.1
Drinking (%) 0.154
Ever had 29.2 19.6 27.2
Never had 70.8 80.4 72.8
AJCC stage classification (%) 0.576
Stage I 14.4 21.4 15.8
Stage II 28.2 25.0 27.6
Stage III 39.4 33.9 38.2
Stage IV 18.1 19.6 18.4
Active CRC treatment (%) 0.338
No 76.4 78.6 76.8
Adjuvant 9.3 3.6 8.1
Palliative 14.4 17.9 15.1
Stoma (%) 0.482
Present 12.5 16.1 13.2
Absent 87.5 83.9 86.8
CRC, colorectal cancer; AJCC, American Joint Committee on Cancer.
 Significant difference between model development and validation group by t test or w2 test.
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observed range of SF-6D and most of the QLQ-C30 and QLQ-
CR29subset scale scores were the same as the possible range in the
model development group while these ranges were narrower than
the possible range in the model validation group. No floor effect
was observed in SF-6D in both groups, but there was a slight ceiling
effect, with 6.6% of the subjects having an upper bound of 1 in both
samples. The global health status and functional scale scores of
QLQ-C30 scales and functional scale scores of QLQ-CR29subset scales
had a ceiling effect (420%), and symptom scale scores of QLQ-C30
scales and QLQ-CR29subset scales had a floor effect (420%) in both
groups.
Regression Models Using Scale Scores
Regression models and their goodness of fit are summarized in
Table 3a and Table 3b. Significant variables in the models using
the QLQ-C30 scale were slightly different from models using the
QLQ-C30 supplemented with the QLQ-CR29subset. The main-effect
terms selected from the QLQ-C30 scale scores in model S1 were
QL, PF, EF, SF, FA, PA, and DI scale scores. Then, the square term of
SF and the two interaction terms of PF  EF and FA  EF were
added in model S2. The influence of the main-effect terms of PFand SF, however, changed to not significant after the square
terms and interactions terms were added to S2. All clinical and
demographic factors were not significant (model not shown).
When selecting scale scores from the QLQ-C30 supplemented
with the QLQ-CR29subset, the SF scale was replaced by the BI scale
in the main-effects term in model S4. Then, the square term of DI
and the two interaction terms of PF  BI and QL  EF were
included but the main-effect terms of QL, PF, EF, and BI were
insignificant in model S5. Model S6 also included the demo-
graphic variable of sex.
Regression Models Using Item Responses
Regression models and their goodness of fit are summarized in
Table 4a and Table 4b. Significant variables were similar for
models estimated by using QLQ-C30 data only and models using
QLQ-C30 data supplemented with the QLQ-CR29subset. In the first
model R1, the main-effect terms selected from the QLQ-C30 were
PF(Q2 and Q5), FA(Q12 and Q18), SF(Q26), and QL(Q30) scales. For
model R4 estimated by using QLQ-C30 and QLQ-CR29subset data,
the main-effect terms of PA(Q9), SF(Q27), and BI(Q46) were added
but SF(Q26) and QL(Q30) were excluded. In models R2 and R5, the
interaction term PF(Q2)  FA(Q18) was added but variable FA(Q18)
Table 2 – Descriptive statistics for SF-6D preference-based and QLQ-C30/CR29subset scale scores.
Model development (n ¼ 216) Model validation (n ¼ 56) Total (n ¼ 272)
Mean  SD 95% CI Floor
(%)
Ceiling
(%)
Observed
range
Mean  SD 95% CI Floor
(%)
Ceiling
(%)
Observed
range
Mean  SD 95% CI Floor
(%)
Ceiling
(%)
Observed
range
Preference-based score
SF-6Dy 0.760  0.161 0.738–0.782 0.9 5.6 0.315–1 0.844  0.144 0.805–0.882 0.0 10.7 0.385–1 0.777  0.161 0.758–0.796 0.7 6.6 0.315– 1
QLQ-C30 Scale scorez
QL 72.1  20.7 69.4– 74.9 0.0 17.6 16.7–100 68.8  17.9 63.9– 73.6 0.0 5.4 25–100 71.4  20.2 69.0– 73.9 0.0 15.1 16.7–100
PF 81.1  16.1 79.0– 83.3 0.5 17.1 0–100 84.4  15.8 80.2– 88.6 0.0 23.2 20–100 81.8  16.1 79.9– 83.7 0.4 18.4 0–100
RF 85.6  21.1 82.7– 88.4 1.4 55.6 0–100 86.3  22.9 80.2– 92.5 1.8 62.5 0–100 85.7  21.5 83.2– 88.3 1.5 57.0 0– 100
EFy 79.9  20.6 77.1– 82.7 0.9 32.9 0–100 90.3  16.1 86.0– 94.6 0.0 53.6 33.3– 100 82.0  20.2 79.6– 84.5 0.7 37.1 0–100
CF 79.9  19.7 77.2– 82.5 0.0 34.7 16.7–100 76.5  18.7 71.5– 81.5 0.0 21.4 16.7–100 79.2  19.6 76.8– 81.5 0.0 32.0 16.7–100
SFy 83.8  21.9 80.9– 86.7 0.9 55.6 0–100 93.8  14.1 90.0– 97.5 0.0 80.4 50–100 85.8  20.9 83.3– 88.3 0.7 60.7 0–100
FAy 27.0  20.6 24.2–29.7 16.7 0.9 0–100 19.4  21.7 13.6–25.3 35.7 0.0 0–77.8 25.4  21.0 22.9– 27.9 20.6 0.7 0–100
NV 5.7  12.1 4.1–7.3 77.8 0.0 0–66.7 2.4  7.4 0.4– 4.4 89.3 0.0 0–33.3 5.0  11.3 3.7– 6.4 80.1 0.0 0–66.7
PA 16.0  18.8 13.4– 18.5 46.8 0.0 0–83.3 15.8  22.6 9.7– 21.8 53.6 0.0 0–83.3 15.9  19.6 13.6– 18.3 48.2 0.0 0–83.3
DY 16.0  21.3 13.2– 18.9 58.8 0.9 0–100 11.9  19.5 6.7–17.1 69.6 0.0 0–66.7 15.2  21.0 12.7– 17.7 61.0 0.7 0–100
SL 23.9  26.7 20.3– 27.5 45.4 4.6 0–100 27.4  34.9 18.0– 36.7 51.8 12.5 0–100 24.6  28.5 21.2– 28.0 46.7 6.3 0–100
AP 13.3  22.2 10.3– 16.3 68.5 1.9 0–100 11.3  20.4 5.9– 16.8 73.2 0.0 0– 66.7 12.9  21.9 10.3– 15.5 69.5 1.5 0–100
COy 22.2  26.5 18.7– 25.8 50.5 3.2 0–100 13.7  22.7 7.6– 19.8 67.9 1.8 0–100 20.5  26.0 17.4– 23.6 54.0 2.9 0–100
DI 14.0  21.4 11.2– 16.9 64.8 1.4 0–100 9.5  17.7 4.8– 14.3 75.0 0.0 0–66.7 13.1  20.7 10.6– 15.6 66.9 1.1 0–100
FIy 27.0  30.3 22.9–31.1 46.3 6.0 0–100 13.1  26.7 5.9– 20.3 75.0 5.4 0–100 24.1  30.1 20.6– 27.7 52.2 5.9 0–100
QLQ-CR29subset scale score
z
BI 84.5  21.8 81.5– 87.4 1.0 55.3 0–100 90.8  24.6 84.0– 97.6 3.8 83.0 0–100 85.7  22.5 83.0– 88.5 1.5 60.9 0–100
ANXy 67.3  27.4 63.6– 71.1 5.3 29.3 0–100 80.5  25.7 73.4– 87.6 3.8 54.7 0–100 70.0  27.5 66.6– 73.3 5.0 34.5 0–100
DM 22.1  23.9 18.8– 25.4 45.2 2.9 0–100 17.6  20.3 12.0– 23.2 52.8 0.0 0–67 21.2  23.2 18.4– 24.0 46.7 2.3 0–100
BFy 12.3  19.2 9.7– 15.0 67.3 0.5 0–100 2.5  8.9 0.1– 5.0 92.5 0.0 0–33 10.3  18.0 8.2– 12.5 72.4 0.4 0–100
APAINy 8.5  15.6 6.4–10.6 76.0 0.0 0–67 0.6  4.6 0.6 to 1.9 98.1 0.0 0–33 6.9  14.4 5.1–8.7 80.5 0.0 0–67
DYSU 5.3  13.5 3.4– 7.1 85.6 13.0 0–67 1.9  7.8 0.3 to 4.0 94.3 5.7 0–33 4.6  12.6 3.1–6.1 87.4 11.5 0–67
UF 22.8  21.1 19.9–25.6 30.3 0.5 0–100 19.5  17.2 14.8– 24.2 28.3 0.0 0–67 22.1  20.3 19.6– 24.6 29.9 0.4 0–100
ANX, anxiety; AP, appetite loss; APAIN, abdominal pain; BF, bloating; BI, body image; CF, cognitive functioning; DI, diarrhea; DM, dry mouth; DY, dyspnea; DYSU, dysuria; CO, constipation; EF,
emotional functioning; FA, fatigue; FI, financial difficulties; NV, nausea and vomiting; PA, pain; PF, physical functioning; QL, global health status/quality of life; RF, role functioning; SF, social
functioning; SF-6D, six-dimensional health state short form; SL, insomnia; UF, Urinary frequency.
* Theoretical range of SF-6D preference-based scores is 0.315–1.000.
y Significant difference between model development and validation group by t test.
z Theoretical range of each QLQ-C30/CR29subset score is 0–100.
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Table 3a – Prediction models for patients with colorectal cancer using main effects, squared terms, interaction
terms of QLQ-C30/CR29subset scale scores, and clinical and demographic variables.
Scale scores
Main effects (S1) Squared terms and interaction terms added (S2)
Coefficient 95% CI Coefficient 95% CI
Main
QL 0.00134 0.00049–0.00220 0.00138 0.00054–0.00221
PF 0.00255 0.00143–0.00367 0.00231 0.00534 to 0.00072
EF 0.00113 0.00024–0.00203 0.00556 0.00982 to 0.00131
SF 0.00105 0.00022–0.00188 0.00212 0.00529 to 0.00105
FA 0.00155 0.00252 to 0.00058 0.00402 0.00647 to 0.00157
PA 0.00132 0.00218 to 0.00045 0.00130 0.00213 to 0.00047
DI 0.00074 0.00011–0.00136 0.00092 0.00031–0.00152
Squared
SF2 0.00002 0.00000–0.00005
Interaction
PF  EF 0.00007 0.00003–0.00011
FA  EF 0.00004 0.00000–0.00007
Constant 0.33030 0.19254–0.46806 0.87272 0.56941–1.17603
Goodness of fit
R2 68.99% 72.70%
Adjusted R2 67.95% 71.30%
AIC 412.97 434.29
BIC 385.97 397.16
Predictive performance
r 0.831 0.853
ICC 0.899 0.869–0.923 0.914 0.888–0.935
RMSE 0.090 0.084
MAE 0.072 0.068
AE4 0.05 122 (56.48%) 120 (55.56%)
AE4 0.10 56 (25.93%) 53 (24.54%)
Range of fitted values 0.088–0.962 0.372– 0.985
AE, absolute error; AIC, Akaike information criterion; BIC, Bayesian information criterion; CI, confidence interval; DI, diarrhea; EF, emotional
functioning; FA, fatigue; ICC, intraclass correlation; MAE, mean absolute error; PA, pain; PF, physical functioning; QL, global health status/
quality of life; RMSE, root mean squared error; SF, social functioning.
 Significant with P valueo 0.05.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 7 3 – 3 8 4378became insignificant. The presence of a stoma had a negative
coefficient in models R3 and R6. The female dummy variable was
significant in model R3 but was insignificant and excluded in
model R6.
Comparison Across All Models
The best models using scale and item responses were S6 and R6,
respectively. (See SPSS syntax Appendices 2 and 3 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2012.12.
004.) The PF and FA scale scores were significant in the scale
models, and those underlying items were significant in item
responses models. Models R6 and S6 differed in their model
specifications because S6 included all main-effect variables
whereas R6 retained only significant items. However, the scales
that had significant variables varied across the two models. In
model R6, main effects for FA, PA, and DI were significant,
whereas in model S6, items from scales of PF, PA, FA, SF, and BI
were significant. Predictive performance was similar in models S6
and R6. For example, Spearman’s correlation coefficients were
about 0.87, and the RMSE and MAE were 0.08 and around 0.07
respectively, indicating low extent of predictive error with high
level of accurate predictions. In addition, Table 5 demonstrates
the differences between the predicted and observed SF-6D scores.
There was overprediction for more severe health states when the
observed SF-6D score was smaller than 0.7 and vice versa (Fig. 2).With regard to goodness of fit, however, model S6 yielded highest
adjusted R2, AIC, and BIC among all models.
Model Validation
Table 6 shows the predictive performance of the models using the
out-of-sample validation data set. For all models, ME ranged from
0.045 to 0.063. RMSE and MAE were approximately 0.10 and 0.08
in all models except the QLQ-C30 item response models R1 to R3,
which had a slightly larger value of 0.115 to 0.128 and 0.095 to
0.102, respectively. Spearman’s correlation coefficients were
around 0.8 and 0.7 in the scale and item response models,
respectively, indicating high associations between the predicted
and observed SF-6D scores. Correlation was high for Kontodimo-
poulos’s predictions, but predictive performance was much
poorer. Although the Spearman’s correlation coefficient was the
greatest between observed SF-6D scores and predicted SF-6D
scores produced using the Kontodimopoulos’s model, the ME,
RMSE, and MAE were above 0.3 and the proportion of subjects
with an absolute error of more than 0.05 was more than 95%.Discussion
This study predicted SF-6D utility scores by using both item
responses and scale scores of the QLQ-C30 and QLQ-CR29subset
Table 3b – Prediction models for patients with colorectal cancer using main effects, squared terms, interaction
terms of QLQ-C30/CR29subset scale scores, and clinical and demographic variables.
Scale scores
Main effects (S4) Squared terms and interaction
terms added (S5)
Clinical and demographic
variables added (S6)
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
Main
QL 0.00128 0.00059–0.00197 0.00172 0.00411 to 0.00067 0.00150 0.00387 to 0.00087
PF 0.00273 0.00159–0.00387 0.00014 0.00210 to 0.00237 0.00006 0.00228 to 0.00215
EF 0.00145 0.00231 to 0.00059 0.00077 0.00261 to 0.00107 0.00070 0.00252 to 0.00112
BI 0.00125 0.00040–0.00209 0.00179 0.00394 to 0.00035 0.00177 0.00389 to 0.00036
FA 0.00130 0.00049–0.00212 0.00098 0.00191 to 0.00005 0.00108 0.00200 to 0.00015
PA 0.00132 0.00227 to 0.00036 0.00153 0.00235 to 0.00071 0.00153 0.00233 to 0.00072
DI 0.00069 0.00007–0.00131 0.00207 0.00082–0.00332 0.00212 0.00089–0.00336
Squared
DI2 0.00002 0.00004 to 0.00000 0.00004 0.00001–0.00007
Interaction
PF  BI 0.00004 0.00001–0.00007 0.00003 0.00001–0.00006
QL  EF 0.00003 0.00001–0.00006 0.00002 0.00004 to 0.00000
Demographic
Female 0.02753 0.05088 to 0.00418
Constant 0.28427 0.14620–0.42234 0.61961 0.42730–0.81191 0.64180 0.45067–0.83293
Goodness of fit
R2 70.97% 74.30% 75.02%
Adjusted R2 69.95% 73.00% 73.61%
AIC 407.89 430.47 432.12
BIC 384.52 393.75 394.07
Predictive performance
r 0.838 0.862 0.866
ICC 0.908 0.879–0.930 0.921 0.896–0.940 0.924 0.900–0.942
RMSE 0.087 0.082 0.080
MAE 0.070 0.065 0.065
AE4 0.05 121 (58.17%) 116 (55.77%) 107 (51.44%)
AE4 0.10 55 (26.44%) 47 (22.60%) 44 (21.15%)
Range of fitted
values
0.127–0.944 0.306–1.011 0.323–0.993
AE, absolute error; AIC, Akaike information criterion; BI, body image; BIC, Bayesian information criterion; CI, confidence interval; DI, diarrhea;
EF, emotional functioning; FA, fatigue; ICC, intraclass correlation; MAE, mean absolute error; PA, pain; PF, physical functioning; QL, global
health status/quality of life; RMSE, root mean squared error; SF, social functioning.
 Significant with P valueo 0.05.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 7 3 – 3 8 4 379measures in patients with CRC. Models containing the QLQ-C30
scale and QLQ-CR29subset item response scores fitted satisfacto-
rily on the basis of commonly reported statistical indicators
(R2 and adjusted R2), with exploratory power achieving at least
67% [11]. The mapping models described in this article had better
performance than did mapping models we recently developed
from Functional Assessment of Cancer Therapy-General or Func-
tional Assessment of Cancer Therapy-Colorectal subscale scores
on the basis of patients with colorectal neoplasms (including
polyps) in terms of exploratory power and predictive perfor-
mance [30]. Models estimated by using item responses had
superior exploratory power and predictive performance to mod-
els estimated from scale scores only. Conversely, AIC and BIC
information criterions for item response models were generally
worse (less negative) than those of scale models. An interesting
pattern for information criterions was observed among item
models because an increased number of independent variables
led to positive changes in the information criterions, suggesting
that the simpler models with fewer variables are preferred. The
addition of the QLQ-CR29subset measure provided a larger numberof functional and symptom variables for consideration, but it did
not always lead to improved model performance and consider-
able increase in R2 and adjusted R2. Although model S4 including
the main effect of QLQ-C30 and QLQ-CR29subset scale scores had
the highest Spearman’s correlation coefficient and lowest RMSE
using the validation out-of-sample data set, the most preferred
and best-performing model in terms of predictive performance
was model S6, which included the main and interaction effects of
QLQ-C30 and QLQ-CR29subset scale scores plus sex variable.
Of particular interest was whether the inclusion of demo-
graphic variables as explanatory variables improved model per-
formance. Previous studies found that age was a significant
independent variable when mapping QLQ-C30 to the EQ-5D
questionnaire [20,26,38–40], but the results of this study did not
find age to be statistically significant when predicting SF-6D
scores. The significance of age found in other studies could be
related to the type of cancer or the age range of the populations
included in the model development studies. Sex was significant
in two studies mapping QLQ-C30 to the EQ-5D questionnaire
[20,39] but not in one other study [38]. Our results found that the
Table 4a – Prediction models for patients with colorectal cancer using main effects, interaction terms of QLQ-
C30/CR29subset item scores, and clinical and demographic variables.
Item response scores
Main effects (R1) Interaction terms added (R2) Clinical and demographic
variables added (R3)
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
Main
PF(Q2_1)
Q2_2 0.07208y 0.10292 to 0.04123 0.04819y 0.09507 to 0.00132 0.05156y 0.09708 to 0.00605
Q2_3_4 0.12974y 0.17954 to 0.07994 0.26551y 0.37486 to 0.15616 0.27638y 0.38244 to 0.17032
PF(Q5_1)
Q5_2_3_4 0.13395y 0.19953 to 0.06837 0.12106y 0.18616 to 0.05596 0.11488y 0.17833 to 0.05142
FA(Q12_1)
Q12_2 0.04324y 0.07660 to 0.00988 0.04136y 0.07444 to 0.00828 0.04643y 0.07864 to 0.01423
Q12_3_4 0.08088y 0.14361 to 0.01815 0.09858y 0.16166 to 0.03551 0.10082y 0.16202 to 0.03963
FA(Q18_1)z
Q18_2 0.02416 0.05574 to 0.00741 0.01460 0.05769 to 0.02850 0.01984 0.06168 to 0.02201
Q18_3_4 0.09590y 0.14943 to 0.04237 0.20990y 0.39050 to 0.02929 0.23494y 0.41038 to 0.05949
SF(Q26_1)z
Q26_2 0.05867y 0.09204 to 0.02530 0.05509y 0.08831 to 0.02187 0.05169y 0.08398 to 0.01941
Q26_3_4 0.08498y 0.14715 to 0.02280 0.07326y 0.13525 to 0.01128 0.07175y 0.13179 to 0.01171
QL(Q30_1_2_3)z
Q30_4 0.01725 0.03780 to 0.07230 0.03850 0.01729 to 0.09430 0.05675y 0.00191–0.11159
Q30_5 0.05620y 0.00135–0.11104 0.06761y 0.01334–0.12189 0.07931y 0.02640–0.13221
Q30_6 0.06669y 0.01095–0.12243 0.08014y 0.02463–0.13566 0.09305y 0.03882–0.14727
Q30_7 0.10181y 0.03935–0.16427 0.11784y 0.05542–0.18026 0.13199y 0.07111–0.19287
Interaction
PF(Q2_1)  FA(Q18_1)y
Q2_2  Q18_2 0.03696 0.09523 to 0.02131 0.02229 0.07932 to 0.03474
Q2_2  Q18_3_4 0.08776 0.10213 to 0.27764 0.12598 0.05895 to 0.31092
Q2_3_4 Q18_2 0.14102y 0.02006–0.26198 0.18398y 0.06478–0.30319
Q2_3_4  Q18_3_4 0.29118y 0.07159–0.51077 0.33265y 0.11882–0.54649
Clinical
Presence of stoma99 0.05392y 0.01731–0.09053
Demographic
Female99 0.03402y 0.05804 to 0.01000
Constant 0.83754y 0.77675–0.89833 0.81940y 0.75647–0.88232 0.77227y 0.70023–0.84430
Goodness of fit
R2 70.99% 72.63% 74.59%
Adjusted R2 69.13% 70.28% 72.13%
AIC 403.41 397.97 406.01
BIC 368.15 359.22 364.50
Predictive performance
r 0.843 0.852 0.864
ICC 0.908 0.879–0.929 0.914 0.888–0.934 0.922 0.898–0.940
RMSE 0.087 0.084 0.081
MAE 0.070 0.067 0.063
AE4 0.05 126 (58.33%) 119 (55.09%) 113 (52.31%)
AE4 0.10 51 (23.61%) 50 (23.15%) 43 (19.91%)
Range of fitted values 0.312–0.939 0.342–0.937 0.360–0.958
Note. Item variables were described as the item number with the response level of the item. For example, Q2_1 is defined as level 1 of item
Q2.AE, absolute error; AIC, Akaike information criterion; BIC, Bayesian information criterion; CI, confidence interval; FA, fatigue; ICC,
intraclass correlation; MAE, mean absolute error; PF, physical functioning; QL, global health status/quality of life; RMSE, root mean squared
error; SF, social functioning.
 Significant variable for R1, R2, and R3.
y Significant coefficient with P valueo 0.05.
z Significant variable for R1.
y Significant variable for R2 and R3.
99 Significant variable for R3.
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Table 4b – Prediction models for patients with colorectal cancer using main effects, interaction terms of QLQ-
C30/CR29subset item scores, and clinical and demographic variables.
Item response scores
Main effects (R4) Interaction terms added (R5) Clinical and demographic
variables added (R6)
Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI
Main
PF(Q2_1)
Q2_2 0.06974y 0.10030 to 0.03918 0.05654y 0.10174 to 0.01134 0.05929y 0.10378 to 0.01480
Q2_3_4 0.12886y 0.17927 to 0.07845 0.26874y 0.37544 to 0.16204 0.27591y 0.38075 to 0.17107
PF(Q5_1)
Q5_2_3_4 0.11163y 0.17225 to 0.05102 0.09638y 0.15692 to 0.03583 0.09324y 0.15302 to 0.03346
PA(Q9_1)
Q9_2 0.04106y 0.06929 to 0.01283 0.03388y 0.06198 to 0.00577 0.03313y 0.06075 to 0.00552
Q9_3_4 0.05290 0.11415 to 0.00835 0.06130y 0.12170 to 0.00090 0.05517 0.11459 to 0.00424
FA(Q12_1)
Q12_2 0.04282y 0.07580 to 0.00984 0.03995y 0.07275 to 0.00715 0.04535y 0.07776 to 0.01294
Q12_3_4 0.06182 0.12583 to 0.00219 0.07495y 0.13908 to 0.01082 0.07895y 0.14215 to 0.01576
FA(Q18_1)z
Q18_2 0.01791 0.04871 to 0.01290 0.01808 0.05987 to 0.02370 0.02229 0.06342 to 0.01883
Q18_3_4 0.08512y 0.13814 to 0.03210 0.18249y 0.35787 to 0.00712 0.20175y 0.37458 to 0.02892
SF(Q27_1)
Q26_2 0.06625y 0.09785 to 0.03466 0.07138y 0.10266 to 0.04010 0.06689y 0.09778 to 0.03599
Q26_3_4 0.09200y 0.13995 to 0.04404 0.09562y 0.14332 to 0.04793 0.09878y 0.14571 to 0.05185
BI(Q46_1)
Q46_2 0.00595 0.03657 to 0.02468 0.00575 0.03590 to 0.02440 0.01004 0.03976 to 0.01969
Q46_3_4 0.07152y 0.11158 to 0.03147 0.06708y 0.10681 to 0.02734 0.06539y 0.10484 to 0.02595
Interaction
PF(Q2_1)  FA(Q18_1)y
Q2_2  Q18_2 0.01929 0.07609 to 0.03750 0.00631 0.06276 to 0.05013
Q2_2  Q18_3_4 0.07261 0.11196 to 0.25719 0.10235 0.07992 to 0.28463
Q2_3_4  Q18_2 0.14759y 0.02781 to 0.26737 0.17942y 0.05991 to 0.29893
Q2_3_4  Q18_3_4 0.27643y 0.06221–0.49066 0.29301y 0.08206–0.50397
Clinical
Presence of stoma99 0.04525y 0.00806–0.08244
Demographic
Female99 0.02546y 0.04991 to 0.00100
Constant 0.93175y 0.90459–0.95891 0.93145y 0.90137–0.96152 0.90303y 0.85845–0.94761
Goodness of fit
R2 72.86% 74.37% 75.58%
Adjusted R2 71.04% 72.08% 73.11%
AIC 398.90 392.82 394.87
BIC 366.17 356.74 356.11
Predictive performance
r 0.854 0.862 0.869
ICC 0.915 0.889–0.935 0.926 0.902–0.943 0.921 0.896–0.940
RMSE 0.084 0.081 0.080
MAE 0.066 0.063 0.062
AE4 0.05 111 (53.37%) 106 (50.96%) 103 (49.52%)
AE4 0.10 54 (25.96%) 53 (25.48%) 45 (21.63%)
Range of fitted values 0.328– 0.932 0.354– 0.931 0.343– 0.948
Note. Item variables were described as the item number with the response level of the item. For example, Q2_1 is defined as level 1 of item
Q2.AE, absolute error; AIC, Akaike information criterion; BI, body image; BIC, Bayesian information criterion; CI, confidence interval; FA,
fatigue; ICC, intraclass correlation; PF, physical functioning; SF, social functioning; MAE, mean absolute error; PA, pain; RMSE, root mean
squared error.
* Significant variable for R1, R2, and R3.
y Significant coefficient with P valueo 0.05.
z Significant variable for R1.
y Significant variable for R2 and R3.
99 Significant variable for R3.
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Table 5 – Mean error, RMSE, and MAE of predicted compared with observed SF-6D preference-based scores by
their ranges for QLQ-C30/CR29subset scale and item scores prediction models.
Scale
(QLQ-30)
Scale (QLQ-30/
CR29subset)
Item
(QLQ-30)
Item (QLQ-30/
CR29subset)
Observed
SF-6D range
S1 S2 S4 S5 S6 R1 R2 R3 R4 R5 R6
Mean error
0.315–0.500 (n ¼ 10) 0.033 0.048 0.030 0.035 0.058 0.044 0.040 0.028 0.031 0.027 0.024
0.501–0.600 (n ¼ 32) 0.064 0.049 0.066 0.050 0.054 0.050 0.047 0.046 0.062 0.058 0.057
0.601–0.700 (n ¼ 39) 0.085 0.070 0.076 -0.081 0.058 0.083 0.078 0.072 0.075 0.073 0.066
0.701–0.800 (n ¼ 35) 0.015 0.020 0.014 0.013 0.020 0.015 0.013 0.012 0.025 0.025 0.023
0.801–0.900 (n ¼ 45) 0.034 0.028 0.033 0.030 0.030 0.032 0.030 0.026 0.031 0.028 0.026
0.901–1.000 (n ¼ 55) 0.066 0.054 0.059 0.056 0.043 0.060 0.057 0.054 0.050 0.048 0.046
Whole range (n ¼ 216) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
RMSE
0.315–0.500 (n ¼ 10) 0.120 0.079 0.119 0.102 0.100 0.105 0.101 0.095 0.093 0.094 0.095
0.501–0.600 (n ¼ 32) 0.098 0.088 0.100 0.085 0.079 0.084 0.083 0.086 0.098 0.090 0.091
0.601–0.700 (n ¼ 39) 0.113 0.107 0.109 0.116 0.097 0.120 0.113 0.106 0.107 0.104 0.097
0.701–0.800 (n ¼ 35) 0.080 0.080 0.082 0.069 0.085 0.067 0.068 0.065 0.074 0.076 0.075
0.801–0.900 (n ¼ 45) 0.061 0.066 0.063 0.071 0.070 0.072 0.072 0.069 0.073 0.072 0.070
0.901–1.000 (n ¼ 55) 0.085 0.078 0.074 0.073 0.069 0.079 0.076 0.073 0.069 0.066 0.065
Whole range (n ¼ 216) 0.090 0.084 0.087 0.084 0.080 0.087 0.084 0.081 0.084 0.081 0.080
MAE
0.315–0.500 (n ¼ 10) 0.093 0.052 0.089 0.074 0.076 0.087 0.076 0.076 0.074 0.068 0.075
0.501–0.600 (n ¼ 32) 0.086 0.077 0.087 0.068 0.064 0.069 0.067 0.066 0.077 0.070 0.071
0.601–0.700 (n ¼ 39) 0.095 0.088 0.094 0.094 0.082 0.103 0.093 0.083 0.090 0.085 0.078
0.701–0.800 (n ¼ 35) 0.061 0.065 0.062 0.057 0.067 0.055 0.057 0.052 0.057 0.059 0.059
0.801–0.900 (n ¼ 45) 0.050 0.056 0.049 0.057 0.057 0.058 0.057 0.058 0.058 0.057 0.057
0.901–1.000 (n ¼ 55) 0.070 0.061 0.063 0.059 0.055 0.063 0.060 0.057 0.054 0.052 0.051
Whole range (n ¼ 216) 0.072 0.068 0.070 0.066 0.065 0.070 0.067 0.063 0.066 0.063 0.062
MAE, mean absolute error; RMSE, root mean squared error; SF-6D, six-dimensional health state short form.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 7 3 – 3 8 4382addition of sex and the presence of a stoma improved the
predictive performance and goodness of fit with a negligible
increase in model complexity.
Some models estimated by using scale variables had counter-
intuitive or inconsistent signs for some explanatory variables. For
example, more severe diarrhea or worse emotional functioning
led to higher SF-6D scores. For original models estimated by using
item responses, all regression coefficients were consistent where
more severe levels led to lower SF-6D scores with the exception of
the PF item Q4 in models R4 to R6. One solution for inconsistent0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1219161311
Fig. 2 – The scatter plot of mean observed and predicted
SF-6D preference-based values by the health state ranking
in descending order of the mean observed values. SF-6D,
six-dimensional health state short form.signs is to merge adjacent levels of this item, following the
procedures proposed by the developers of country-specific SF-
6D scoring algorithms [35–37,41]. The effect of the PF item Q4 was
found to be insignificant after the merger of item Q4 levels.
A review of the literature on mapping QLQ-C30 to the EQ-5D
questionnaire shows that 7 of 10 models had an R2 of 49% to 80%,
to which our models with an R2 of 69% to 76% are comparable.
The predictive performance of our models is better than that of
existing models mapping QLQ-C30 to SF-6D. This may be because
our development and validation data sets were all from CRC
while existing models used data from a variety of cancer types,
cancer stages, and cultures based on patients in different
countries.
Studies mapping to the EQ-5D questionnaire often found
models overpredicted better health states but underpredicted
poorer health states, as indicated using graphs showing observed
and predicted preference-based scores [19,22,30,38,40,42–47]. The
pattern was different in our model mapping QLQ-C30 and QLQ-
CR29subset to SF-6D in that the largest errors were observed in SF-
6D scores between 0.601 and 0.700, although errors were in
general higher for more severe health states.
Limitations
This study had several limitations. First, sample size was insuffi-
cient to explore models including dummy variables for each level
of every EORTC QLQ-C30 and QLQ-CR29subset item, but these
models were likely to suffer from multicollinearity. Model esti-
mations using response mapping [48] and probabilistic mapping
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 7 3 – 3 8 4 383[49] were not estimated although patients reported their health
by using the SF-6D dimensions directly. There were not sufficient
samples in all levels of SF-6D. Further research is encouraged to
determine whether response mapping and probabilistic mapping
are better approaches for mapping to SF-6D scores. Second,
regression models were primarily validated by using
interviewer-administered EORTC and SF-6D data, whereas the
models were developed by using self-administered data. We
assumed measure invariance between interviewer- and
self-administration of measures in this article, but this is
questionable based on a study on the colorectal-specific Func-
tional Assessment of Cancer Therapy-Colorectal measure [50].
Further investigation on measurement invariance of the EORTC
measure in respect to modes of administration is needed. How-
ever, validation on interviewer-administered data showed overall
satisfactory model fit, suggesting that these models are robust for
applications using either self-administered or interviewer-
administered data. Finally, our subjects were all Chinese patients
with CRC, recruited from one hospital in Hong Kong, which may
not be fully representative of other Chinese populations. Extra
caution should be taken when applying the mapping functions to
non-Chinese or other disease groups. Therefore, further model
validation of these mapping algorithms should be done by using
data from patients with different ethnicity and types of cancer.Conclusions
EORTC QLQ-C30 and QLQ-CR29 data can be successfully mapped
onto SF-6D for Chinese patients with CRC. The models with the
best predictive performance included sex and stoma variables.
Models estimated by using scale or item responses performed
similarly. The models were validated by using an out-of-sample
data set. These models can be used to estimate SF-6D utility
scores in the calculation of QALYs for future health economic
evaluations when utility data were not collected.
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